South Korea Human Growth Hormone Market Size, Share, and COVID-19 Impact Analysis, By Brand (Norditropin, Humatrope, Saizen, Omnitrope, Skytrofa, and Others), By Application (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, and Others), and South Korea Human Growth Hormone Market Insights, Industry Trend, Forecasts to 2035

South Korea Human Growth Hormone Market Insights Forecasts to 2035

• The South Korea Human Growth Hormone Market Size was estimated at USD 180.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.28% from 2025 to 2035
• The South Korea Human Growth Hormone Market Size is Expected to Reach USD 479.0 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Human Growth Hormone Market Size is Anticipated to Reach USD 479.0 Million by 2035, Growing at a CAGR of 9.28% from 2025 to 2035. Driven by the growing number of growth hormone deficiency cases, particularly in children, and the growing need for anti-aging treatments in adults. The market is growing at an even faster rate thanks to biotechnology advancements, encouraging government policies, and increased accessibility to recombinant HGH products.

Market Overview

The healthcare and pharmaceutical industries centered on the creation, marketing, and use of growth hormone treatments to address hormone deficiencies and associated disorders are referred to as the South Korea Human Growth Hormone (HGH) Market. Additionally, recent HGH products are developed and approved more quickly in South Korea thanks to the government's encouragement of creative healthcare research and solutions. Furthermore, an important market driver is the growing number of people seeking HGH therapies due to the prevalence of lifestyle diseases. There are many market opportunities, especially given the rising demand for alternative and non-invasive treatments. The South Korean healthcare system is evolving, and a lot of patients are searching for both conventional and contemporary forms of treatment. Pharmaceutical firms and medical providers may be able to offer specialized HGH treatments as a result of this. Further, there have been indications of a shift in healthcare recently toward a more individualized approach and meticulous treatment plans for patients.

Report Coverage

This research report categorizes the market for the South Korea human growth hormone market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea human growth hormone market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea human growth hormone market.

Driving Factors

The South Korean human growth hormone market industry has been impacted by the notable upswing in the country's anti-aging treatment market. The demand for human growth hormone as a treatment for age-related conditions is rising, especially among the elderly population, as studies show a 20% annual increase in consumer spending on anti-aging products and therapies. More people are looking for efficient anti-aging treatments, such as hormone replacement therapy, as a result of South Korean society's traditional views on youth and beauty. By creating targeted human growth hormone therapies that specifically address aging-related health improvement, market participants are meeting this demand. Furthermore, according to recent reports from the Korean Ministry of Health and Welfare, public interest in hormone therapies is being heightened by educational campaigns, which in turn is driving market potential.

Restraining Factors

Access is limited in South Korea's HGH market due to limited reimbursement, since national health insurance only covers a few conditions, such as Prader-Willi syndrome, Turner syndrome, and pediatric deficiency. This prevents the widespread adoption of treatment by forcing patients with other growth disorders to pay high out-of-pocket expenses.

Market Segmentation

The South Korea human growth hormone market share is classified into brand and application.

• The norditropin segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea human growth hormone market is segmented by brand into norditropin, humatrope, saizen, omnitrope, skytrofa, and others. Among these, the norditropin segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. In an area like South Korea, where patient-friendliness in medical treatments is highly valued, norditropin stands out for its novel pen delivery system that makes administration easier for patients.

• The pediatric growth hormone deficiency segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea human growth hormone market is segmented by application into pediatric growth hormone deficiency, adult growth hormone deficiency, idiopathic growth hormone deficiency, small for gestational age, turner syndrome, prader-willi syndrome, and others. Among these, the pediatric growth hormone deficiency segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Since early identification and treatment can significantly improve children's growth outcomes and lay the groundwork for long-term health, pediatric growth hormone deficiency is a serious concern.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea human growth hormone market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• LG Chem
• Hanmi Pharmaceutical
• Daewoong Pharmaceutical
• Kolmar Korea
• Others

Recent Developments:

• In June 2024, South Korea announced a crackdown on false or exaggerated advertisements for growth hormone treatments, as the private market for height-enhancement products grew there.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Human Growth Hormone Market based on the below-mentioned segments:

South Korea Human Growth Hormone Market, By Brand

• Norditropin
• Genotropin
• Humatrope
• Saizen
• Omnitrope
• Skytrofa
• Others

South Korea Human Growth Hormone Market, By Application

• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency
• Idiopathic Growth Hormone Deficiency
• Small for Gestational Age
• Turner Syndrome
• Prader-Willi Syndrome
• Others